Sugi Predict

Sugi Predict / Compounds / SCHEMBL425369

SCHEMBL425369

SCHEMBL425369

NC(=O)N(c1ccc(-c2ccc(F)c3onc(N)c23)cc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 16/20 0.49
▸ FLT3 P36888 15/20 0.49
▸ KIT P10721 13/20 0.49
▸ FLT1 P17948 5/20 0.49
▸ CSF1R P07333 4/20 0.49
▸ PDGFRB P09619 3/20 0.49
▸ TEK Q02763 3/20 0.49
▸ IKBKE Q14164 1/20 0.43
▸ AURKA O14965 2/20 0.40
▸ DYRK3 O43781 2/20 0.40
▸ ROCK2 O75116 2/20 0.40
▸ RPS6KA5 O75582 2/20 0.40
▸ PRKD3 O94806 2/20 0.40
▸ MAP4K4 O95819 2/20 0.40
▸ NTRK1 P04629 2/20 0.40
▸ LCK P06239 2/20 0.40
▸ FYN P06241 2/20 0.40
▸ LYN P07948 2/20 0.40
▸ RET P07949 2/20 0.40
▸ FGFR1 P11362 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5257214 0.90 KDR (0.51) KDRFLT3KITFLT1CSF1R
SCHEMBL27636449 0.88 KDR (0.49) KDRFLT3KITFLT1CSF1R
SCHEMBL27657281 0.88 KDR (0.47) KDRFLT3KITFLT1CSF1R
SCHEMBL27636473 0.87 KDR (0.47) KDRFLT3KITFLT1CSF1R
SCHEMBL27657338 0.87 KDR (0.55) KDRFLT3KITFLT1CSF1R
SCHEMBL6805276 0.87 FLT3 (0.66) KDRFLT3KITFLT1CSF1R
SCHEMBL27657353 0.85 KDR (0.62) KDRFLT3KITFLT1CSF1R
SCHEMBL27636410 0.85 KDR (0.45) KDRFLT3KITFLT1CSF1R
SCHEMBL27636397 0.82 IKBKE (0.62) KDRFLT3KITFLT1CSF1R
SCHEMBL27657341 0.81 KDR (0.54) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 — — EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 — — WO claimed
CN-1826324-A Indazole, benzisoxazole and benzisothiazole kinase inhibitors ABBOTT LAB (US) 2006-08-30 — — CN claimed
US-8299243-B2 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors ABBVIE INC. (US) 2012-10-30 — — US disclosed
US-20120022253-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2012-01-26 — — US disclosed
CN-101827584-A Solid dispersion product of N-aryl ureido drugs ABBOTT GMBH & CO KG 2010-09-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022253-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABL1, BLK, BTK KDR 724/4885FLT3 41/4885KIT 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.